AmanMG, KasperW, ManosG, MathewS, MarcusR, OwenR, MankoskiR: Line-item analysis of the Aberrant Behavior Checklist: Results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. J Child Adolesc Psychopharmacol, 20:415–422, 2010.
2.
FindlingRL, MankoskiR, TimkoK, LearsK, McCartneyT, McQuadeRD, EudiconeJM, AmatniekJ, MarcusRN, SheehanJJ: A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry, 75:22–30, 2014.
3.
HoJG, CaldwellRL, McDougleCJ, Orsagh-YentisDK, EricksonCA, PoseyDJ, StiglerKA: The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adoles Psychopharmacol, 22:277–283, 2012.
4.
HuangSC, TsaiSJ, YangHJ: Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder. Chang Gung Med J, 33:211–215, 2010.
5.
KimY, ChoSC, ShinMS, KimJW, LeeSH, KimBN: Retrospective case series of aripiprazole augmentation in pervasive developmental disorders. Psychiatry Investig, 7:220–223, 2010.
6.
MarcusRN, OwenR, KamenL, ManosG, McQuadeRD, CarsonWH, AmanMG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48:1110–1119, 2009.
7.
MarcusRN, OwenR, ManosG, MankoskiR, KamenL, McQuadeRD, CarsonWH, FindlingRL: Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry, 72:1270–1276, 2011.
8.
MasiG, CosenzaA, MillepiediS, MuratoriF, PariC, SalvadoriF: Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: A retrospective study. CNS Drugs, 23:511–521, 2009.
9.
MyersSM, JohnsonCP, American Academy of Pediatrics Council on Children with Disabilities: Management of children with autism spectrum disorders. Pediatrics, 120:1162–1182, 2007.
10.
OwenR, SikichL, MarcusRN, Corey-LisleP, ManosG, McQuadeRD, CarsonWH, FindlingRL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124:1533–1540, 2009.
11.
PolitteLC, McDougleCJ: Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 231:1023–1036, 2014.
12.
PoseyDJ, StiglerKA, EricksonCA, McDougleCJ: Antipsychotics in the treatment of autism. J Clin Invest, 118:6–14, 2008.
13.
StiglerKA, DienerJT, KohnAE, LiL, EricksonCA, PoseyDJ, McDougleCJ: Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: A 14-week, prospective, open-label study. J Child Adoles Psychopharmacol, 19:265–274, 2009.
14.
StiglerKA, McDougleCJ: Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am, 17:739–752, 2008.
15.
StiglerKA, PoseyDJ, McDougleCJ: Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol, 14:455–463, 2004.
16.
Valicenti-McDermottMR, DembH: Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol, 16:549–560, 2006.
17.
Young NJi, FindlingRL: An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry, 28:91–101, 2015.
